NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

# Final appraisal determination

(when no ACD was issued)

|  |
| --- |
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| Not applicable: because this guidance was a review of a published technology appraisal (TA360), no further scoping process was conducted.  No equality issues relevant to committee’s decision making were raised during the scoping or appraisal processes for TA360. |

|  |
| --- |
| 1. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| No potential equality issues were identified in the submissions, expert statements or academic report. |

|  |
| --- |
| 1. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
| Not applicable |

|  |
| --- |
| 1. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
| Not applicable |

|  |
| --- |
| 1. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| Not applicable |

|  |
| --- |
| 1. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE’s obligations to promote equality? |
| Not applicable |

|  |
| --- |
| 1. Have the committee’s considerations of equality issues been described in the final appraisal determination, and, if so, where? |
| Section 3.15 of the FAD specifies that no equalities issues were identified. |

**Approved by Associate Director (name):** Helen Knight

**Date:** 31/08/2017